A Note from Biosimilars Council Executive Director Christine Simmon
2021 proved to be an eventful year for the biosimilars community, with many milestones and positive developments to highlight. Below, you will find policy, regulatory and other developments throughout the year that strengthened patient access to biosimilars.
At the Biosimilars Council, we were proud to bring our industry and stakeholders together to discuss biosimilar developments and trends at AAM’s Access! 2021 and GRx+Biosimilars 2021 conferences. We also illustrated the progress of biosimilar growth and the benefits for patients with the release of the 2021 U.S. Generic and Biosimilar Medicines Savings Report, which found biosimilars providing nearly $8 billion in savings in 2020. In addition to our actions to foster community and demonstrate the growth of the industry, our advocacy efforts earlier in the year contributed to the Advancing Education on Biosimilars Act becoming law, a critical step toward ensuring that clinicians and patients have accurate information about biosimilars, ultimately driving greater adoption of these products. All these measures would not have been possible without the help from stakeholders and members of the Biosimilars Council.
As we come the close of 2021, we are focusing our advocacy efforts to modify the Build Back Better Act to ensure patients can continue to benefit from a competition-based marketplace for biologic medicines. This legislation aims to lower drug prices, but in its current form would jeopardize the savings and increased options for care that biosimilars provide for patients. You can take action today to ensure that patients have access to biosimilars in the years to come.
We are looking ahead to Access! 2022, AAM’s annual meeting February 14-16 in Orlando, Florida. Join us to hear from the leaders driving the future of the biosimilars industry. We hope to see all of you in person then.